Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecularly assigned targeted therapy for chronic myelomonocytic leukemia
ACTRN12621000223831Phase 2Recruiting
- Sponsor
- South Australian Health and Medical Research Institute
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenzilumab, azacitidine and sodium ascorbate in chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by South Australian Health and Medical Research Institute. Primary endpoint: Complete response or partial response rate. Started Sep 2021; status: recruiting.
02
Drugs
lenzilumabazacitidinesodium ascorbate
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on ACTRN12621000223831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000223831.